TANDEM Insights: Trial Results and Clinical Implications

Learn about the promising results of a fixed-dose combination therapy trial that achieved up to a 50% reduction in LDL cholesterol. Steven Nissen, MD and Ashish Sarraju, MD discuss how this CETP inhibitor-based therapy compares to monotherapies, its potential role in treating high-risk cardiovascular patients, and what it could mean for the future of hyperlipidemia management.

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.